Targeting phosphatidylcholine-specific phospholipase C for atherogenesis therapy

HaiYing Li; Lu Zhang; DeLing Yin; Yun Zhang; JunYing Miao

doi:10.1016/j.tcm.2011.02.002

Targeting phosphatidylcholine-specific phospholipase C for atherogenesis therapy

Trends Cardiovasc Med. 2010 Jul;20(5):172-6. doi: 10.1016/j.tcm.2011.02.002.

Authors

HaiYing Li¹, Lu Zhang, DeLing Yin, Yun Zhang, JunYing Miao

Affiliation

¹ Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, Institute of Developmental Biology, School of Life Science, Shandong University, Jinan 250100, China.

PMID: 21742273
DOI: 10.1016/j.tcm.2011.02.002

Abstract

Atherosclerosis, a dynamic and progressive vascular disease arising from the combination of endothelial dysfunction and inflammation, is becoming a major killer in the 21st century. Accumulating evidence implicates phosphatidylcholine-specific phospholipase C (PC-PLC) in endothelial dysfunction and several inflammation processes. In addition, in a recent study, we demonstrated that PC-PLC contributed to the progression of atherosclerosis. Considering the important roles of PC-PLC in vascular endothelial cell dysfunction and its proinflammatory properties, we propose that a pharmacological blockade of PC-PLC represents a rational approach to atherosclerosis therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Atherosclerosis / drug therapy*
Atherosclerosis / enzymology
Humans
Molecular Targeted Therapy
Type C Phospholipases / antagonists & inhibitors*

Substances

Type C Phospholipases
phosphatidylcholine-specific phospholipase C